Menu Search
Equities

J Frontier Co Ltd

R0L:FRA

J Frontier Co Ltd

Actions
  • Price (EUR)18.40
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-31.60%
  • Beta--
Data delayed at least 15 minutes, as of Jul 15 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

J Frontier Co Ltd is a Japan-based company mainly engaged in the electronic commerce sale business for healthcare-related products and pharmaceuticals, the provision of online medication guidance, drug delivery platform SOKUYAKU, as well as the Internet advertising agency business for healthcare-related services. The Company operates through three business segments. The Healthcare Sales segment is engaged in the planning and development of health foods and cosmetics represented by the 328 selection series of fermented hydrogen and mail-order sales. The Medical Care Sales segment is engaged in the operation of dispensing pharmacies, mail-order business of ethical drugs, as well as planning, development and mail-order sales of drugs such as Why Pure series and Chinese herbs. The Health Care Marketing segment is mainly engaged in advertising agency business related to health care products, sales promotion support for health care products, as well as wholesale of in-house products.

  • Revenue in JPY (TTM)17.01bn
  • Net income in JPY-1.71bn
  • Incorporated2008
  • Employees255.00
  • Location
    J Frontier Co Ltd4F, KN Shibuya 3, 9-8, Sakuragaoka-choSHIBUYA-KU 150-0031JapanJPN
  • Phone+81 364274662
  • Fax+81 364275969
  • Websitehttps://jfrontier.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		2934:TYO since
announced		Transaction
value
Wellvenus CorpAnnounced29 Feb 202429 Feb 2024Announced-40.75%10.00m
Data delayed at least 20 minutes, as of Nov 15 2024 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.